Physicians' Academy for Cardiovascular Education

Low hs-CRP associated with lower risk of adverse outcomes in primary prevention cohort

Literature - Sep. 25, 2018 - Penson PE et al. - Eur Heart J 2018

In the REGARDS cohort, low hs-CRP levels were associated with a reduced risk of stroke, and CHD morbidity and mortality, while low LDL-c was not associated with protective effects.

Optimization of diastolic BP associated with reduced CV risk, even at optimal systolic BP

Literature - Sep. 25, 2018 - Boehm M et al. - Eur Heart J 2018

In patients with a systolic BP between 120 and <140 mmHg, a diastolic BP between 70 and <80 mmHg was associated with a lower risk of adverse outcomes as compared to lower and higher DBP.

What is the situation one year after the presentation about the CANTOS trial?

CSI Munich

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA
Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?

ESC 2018 Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?

New SGLT2 inhibitor meets primary safety and HF hospitalization/CV death efficacy endpoint

News - Sep. 24, 2018

Dapagliflozin met the primary safety endpoint of non-inferiority for MACE and showed a significant reduction in the hospitalization for HF or CV death primary efficacy endpoint in DECLARE-TIMI 58.

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom
In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.

In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

ApoC-III distribution in lipoproteins does not provide incremental predictive value for CAD

Literature - Sep. 18, 2018 - van Capelleveen JC et al. - J Clin Lipidol 2018; published online ahead of print

ELISA-based measurement of apolipoprotein C-III on individual lipoproteins did not provide additional predictive information on development of coronary artery disease.

NOAC during AF ablation associated with reduced risk of adverse outcomes

Literature - Sep. 17, 2018 - Kirchhof P et al. - Eur Heart J 2018

Continuous direct factor Xa inhibitor therapy with apixaban was a safe and effective anticoagulation alternative in patients at risk of stroke undergoing atrial fibrillation catheter ablation.

New ESC guidelines on management of CVD during pregnancy

News - Sep. 14, 2018

The new guidelines on management of CVD during pregnancy consider new evidence on diagnostic techniques, risk assessment and drug therapy that became available since the 2012 edition.

ESC debate | First-line therapies in HFrEF - ACE inhibitors or sacubitril/valsartan?

ESC 2018 - debates

ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.